Collegium Pharmaceutical awarded 50,305 restricted stock units (RSUs) on June 1, 2026, to 34 newly hired non-executive employees as an inducement to join the company. These RSUs will vest over three years, starting June 10, 2027, contingent on continued employment. The grants were made under the company's 2026 Inducement Plan, approved by the board to comply with Nasdaq Listing Rule 5635(c)(4). This move aims to attract and retain talent as Collegium continues its focus on innovative treatments for central nervous system and pain conditions.
Whoosh Wellness has launched a new telehealth platform offering physician-guided wellness protocols focused on oral delivery and prescribed microdosing, especially for GLP-1 therapies like semaglutide and tirzepatide. This approach reduces barriers s...
Eos SENOLYTIX presented preclinical results for its MitoXcel™ geropeptide PTC-2105, demonstrating significant muscle mass gains, fat reduction, and improved physical function in aging models. Unlike GLP-1 therapies, PTC-2105 prevents rapid weight reg...
Toobit, a global cryptocurrency exchange, has launched a trading campaign focused on its SpaceX Zone, featuring assets linked to space technology and decentralized finance. Running from June 5 to July 3, 2026, the campaign offers a $200,000 USDT rewa...
Nvidia is moving beyond just supplying GPUs to actively helping AI companies secure physical infrastructure like land, power, and data center capacity needed for large-scale AI deployments. CFO Colette Kress highlighted that the biggest challenge in ...
Brand Engagement Network (BEN) completed a $1 million strategic investment in Accelevate Solutions, gaining about a 10% stake. This move supports their shared goal to expand AI-powered fleet intelligence solutions across North America, Latin America,...
